Veltassa (patiromer)
- Region
- 🇪🇺 EU
- Active substance
- patiromer
- Company
- Vifor Fresenius Medical Care Renal Pharma France
- Status
- Authorised
- Therapeutic area
- Hyperkalemia
- CHMP opinion
- Thu 18 May 2017
- EU approval
- Wed 19 Jul 2017
- Application
- EMEA/H/C/004180
- ATC
- V03AE09
- Official record
- www.ema.europa.eu
Indication
Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.
Regulatory milestones
No milestones recorded in the last year.
Follow Veltassa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.